Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel in Focal Motor Status Epilepticus
NCT04309721Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2022
- Primary completion
- Nov 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in focal motor status epilepticus comparing Perampanel with Placebo (2 arms). Primary endpoint: Administration of an additional second-line or third-line antiepileptic drug at 6 hours. Started Nov 2022; status: terminated.
02
Drugs
perampanel
03
Conditions
focal motor status epilepticus
Beyond the preview
Go deeper on NCT04309721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309721.